Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
Radiolabeled immunotherapy (RIT) is becoming a significant step forward in the treatment management of non-Hodgkin's lymphoma (NHL). In this state-of-the-art review article, general details, practical and health economic aspects, and next steps of RIT in NHL are reviewed from the existing literature and latest abstracts. As 90Y-ibritumomab tiuxetan is the only marketed RIT in NHL in Europe, the special focus of this review is on 90Y-ibritumomab tiuxetan, although the whole spectrum of available RIT concepts is highlighted. There is strong evidence to suggest that RIT is not only a safe and efficacious add-on treatment option in third or second line to chemotherapy, but is also a convincing asset as first-line therapy in various indications of lymphoma.
Otte
Andreas
A
Clinical Trials Center, University Medical Center, Elsässer Str. 2, D-79110 Freiburg, Germany. andreas.otte@uniklinik-freiburg.de
van de Wiele
Christophe
C
Dierckx
Rudi A
RA
D002986:Clinical Trials as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000532:radiotherapy* / Q000628:therapy; D008954:Models, Biological; D011788:Quality of Life; D016499:Radioimmunotherapy / Q000191:economics / Q000379:methods*; D016896:Treatment Outcome